Evogene

Evogene FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Evogene (EVGN) as of Oct 6, 2026 is 160.72 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 123.30 % — a change of 30.35% (higher).

FCF Conversion

160.72 %

YoY

30.35%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Evogene is 2026 160.72 % . FCF Conversion Rate (FCF/EBITDA) of Evogene was 2025 123.30 % . It decreases by 30.35% higher compared to the previous year.

The Evogene FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
74.84 USD
Jan 1, 2019
95.55 USD
Jan 1, 2020
77.07 USD
Jan 1, 2021
83.96 USD
Jan 1, 2022
83.26 USD
Jan 1, 2023
93.65 USD
Jan 1, 2024
123.30 USD
Jan 1, 2025
160.72 USD
The Evogene FCF Conversion history
YEARFCF ConversionYoY
160.72 %+30.35%
123.30 %+31.66%
93.65 %+12.47%
83.26 %-0.84%
83.96 %+8.95%
77.07 %-19.34%
95.55 %+27.67%
74.84 %-5.59%
79.27 %+24.24%
63.81 %-23.79%
83.73 %-2.35%
85.75 %—
Access this data via the Eulerpool API

Evogene Stock analysis

What does Evogene do? Evogene Ltd is an Israeli biotechnology company that focuses on the application of computational biology and genomics to agriculture and biology. The company originated from a spin-off of the Weizmann Institute of Science and was founded in 2002. Today, it is a leading global provider of biotechnology solutions for the agriculture and biotechnology industry. Evogene's business model is based on providing innovative technologies and services for its customers, aiming to improve plant development, particularly in terms of resistance to environmental stress factors and pests. To achieve this, the company utilizes modern biotechnology methods and leverages artificial intelligence. It employs advanced machine learning and large-scale data analysis techniques to gain a better understanding of underlying biological processes. Evogene operates in three core areas: agricultural biotechnology, drug discovery biotechnology, and biomaterials. The company is capable of offering customized biological solutions tailored to the specific needs of its customers. Agricultural biotechnology is one of Evogene's key sectors. It utilizes state-of-the-art technologies and methods to generate plant resistance to pests and environmental factors. With the help of a reliable pipeline of innovative products such as seeds, biostimulants, and fertilizers, Evogene aims to play an important role in food security, environmental sustainability, and resilience to climate change. The company has a strong product pipeline aimed at improving nutrient efficiency of crops while reducing environmental impact from pesticide and fertilizer use. One such product resulting from this pipeline is EvoCanna, which utilizes modern genomics methods to optimize hemp plants in terms of phytocannabinoid biosynthesis. The goal of Evogene's drug discovery biotechnology and biomaterials sector is to develop innovative and effective medicines for diseases such as cancer and obesity. The company utilizes modern machine learning and large-scale data analysis methods to identify the potential of new drug candidates. In the biomaterials sector, Evogene aims to develop innovative technologies and solutions for better and more sustainable use of natural resources. An important application of this concept is biostimulants, which can improve the growth rate, stress tolerance, and yield of crops. Additionally, the company can offer new materials and environmentally friendly solutions in the packaging industry. Overall, Evogene has achieved impressive success in recent years and established itself as a leading biotechnology company. By utilizing cutting-edge technologies, methods, and scientific concepts, particularly artificial intelligence and machine learning, and by operating as a responsible company in the fields of agriculture, biomaterials, and programming, Evogene is able to offer innovative biotechnological solutions. The company is currently well-equipped and has a promising pipeline of groundbreaking innovation projects that embody the desire for a sustainable worldview. Evogene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evogene stock

FCF Conversion Rate (FCF/EBITDA) of Evogene is 160.72 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Evogene changed from 123.30 % to 160.72 %, representing a 30.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Evogene since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Evogene with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Evogene

All Key Metrics — Evogene